SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: William L. Molair II who wrote (9141)3/11/1999 9:13:00 PM
From: aknahow  Read Replies (1) | Respond to of 17367
 

<Also, seems to me that DSMB would have stopped the trial a long time ago if there were not any mengio deaths
in the group of children taking Neuprex.>

Yes, I agree, except that after reading the Robert_S post on the DSMB on the importance of meeting all the FDA conditions, I am no longer sure they could recommend stopping if the target not reached. This does not mean I believe everyone in the treatment group survived.

He was also very bullish on CORR and had details that I thought would appear elsewhere but so far have not. I wonder if they were correct. The market action of CORR indicates it was not impressed. I wish he would get his details straight.



To: William L. Molair II who wrote (9141)3/11/1999 9:23:00 PM
From: Bluegreen  Read Replies (1) | Respond to of 17367
 
I disagree! I think DSMB had all scenarios planned out. They knew it was possible to have zero mortality in treatment group when they picked mortality number requirement. In my opinion the trial could of been stopped early by BOTH mortality requirement fulfilled AND excess efficacy but NOT on just zero mortality in treatment group.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News